ANGO icon

AngioDynamics

12.30 USD
+0.00
0.00%
At close Jan 10, 4:00 PM EST
After hours
12.40
+0.10
0.81%
1 day
0.00%
5 days
34.72%
1 month
38.36%
3 months
100.33%
6 months
119.64%
Year to date
36.97%
1 year
98.71%
5 years
-17.95%
10 years
-35.60%
 

About: AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.

Employees: 748

0
Funds holding %
of 6,814 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

139% more call options, than puts

Call options by funds: $74K | Put options by funds: $31K

58% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 36

24% more capital invested

Capital invested by funds: $205M [Q2] → $254M (+$49.2M) [Q3]

5% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 20

1% less funds holding

Funds holding: 138 [Q2] → 137 (-1) [Q3]

4.12% less ownership

Funds ownership: 84.54% [Q2] → 80.43% (-4.12%) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$15
22%
upside
Avg. target
$15
22%
upside
High target
$15
22%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Yi Chen
48% 1-year accuracy
74 / 155 met price target
22%upside
$15
Buy
Maintained
10 Jan 2025

Financial journalist opinion

Based on 8 articles about ANGO published over the past 30 days

Positive
Zacks Investment Research
3 days ago
AngioDynamics Stock Up on Q2 Earnings Beat, Gross Margin Declines
ANGO registers overall strong top-line results on a pro-forma basis in second-quarter fiscal 2025, driven by strength in the Med Tech business.
AngioDynamics Stock Up on Q2 Earnings Beat, Gross Margin Declines
Positive
Seeking Alpha
4 days ago
AngioDynamics: A Surgical Approach To Market Growth
AngioDynamics, Inc.'s Q2 2025 earnings beat expectations, with non-GAAP EPS at -$0.04 and revenue at $73.02 million, driving a 35% stock surge. Med Tech division shines, with 25% revenue growth and key products like Auryon, AlphaVac, and AngioVac showing strong performance and market acceptance. NanoKnife's FDA clearance and promising clinical trials highlight its potential in prostate cancer treatment, contributing to a 23.1% rise in disposable revenue.
AngioDynamics: A Surgical Approach To Market Growth
Neutral
Seeking Alpha
4 days ago
AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Call Transcript
AngioDynamics, Inc. (NASDAQ:ANGO ) Q2 2025 Earnings Conference Call January 8, 2025 8:00 AM ET Company Participants Jim Clemmer - President and Chief Executive Officer Stephen Trowbridge - Executive Vice President and Chief Financial Officer Conference Call Participants John Young - Canaccord Genuity Steven Lichtman - Oppenheimer Yi Chen - H.C. Wainwright Operator Good morning and welcome to the AngioDynamics Fiscal Year 2025 Second Quarter Earnings Call.
AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Call Transcript
Negative
Zacks Investment Research
4 days ago
AngioDynamics (ANGO) Reports Q2 Loss, Tops Revenue Estimates
AngioDynamics (ANGO) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.05 per share a year ago.
AngioDynamics (ANGO) Reports Q2 Loss, Tops Revenue Estimates
Neutral
Business Wire
4 days ago
AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2025, which ended November 30, 2024. Fiscal Year 2025 Second Quarter Highlights   Quarter Ended November 30, 2024 Pro Forma* YoY Growth Pro Forma* Net Sa.
AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results
Neutral
Business Wire
6 days ago
AngioDynamics to Present at the J.P. Morgan Healthcare Conference
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference at 7:30.
AngioDynamics to Present at the J.P. Morgan Healthcare Conference
Neutral
Business Wire
6 days ago
AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnife™ System
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that the Company will host a virtual investor event on Wednesday, January 8, 2025 at 9:30am ET. This event will take place following the previously announced Fiscal 2025 Second Quarter Financial Results Confer.
AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnife™ System
Neutral
Business Wire
3 weeks ago
AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the second quarter of fiscal year 2025 before the market open on Wednesday, January 8, 2025, followed by a Virtual NanoKnife System investor event. Fiscal 2025 Second Quarte.
AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event
Positive
Zacks Investment Research
1 month ago
ANGO Stock Up Post FDA Nod for Prostate Tissue Ablation With NanoKnife
AngioDynamics' latest regulatory approval is likely to pave the way for an alternative to conventional radical surgery and improve patient outcomes.
ANGO Stock Up Post FDA Nod for Prostate Tissue Ablation With NanoKnife
Positive
Zacks Investment Research
1 month ago
Strength Seen in AngioDynamics (ANGO): Can Its 23.3% Jump Turn into More Strength?
AngioDynamics (ANGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Strength Seen in AngioDynamics (ANGO): Can Its 23.3% Jump Turn into More Strength?
Charts implemented using Lightweight Charts™